Valuation: Clene Inc.

Market Cap 77.95M 68.14M 62.62M 58.37M 111M 7.42B 112M 752M 292M 3.65B 293M 286M 12.57B P/E 2026 *
-3.42x
P/E 2027 * -4.14x
Enterprise Value 64.55M 56.43M 51.86M 48.34M 91.68M 6.15B 93.07M 623M 242M 3.02B 242M 237M 10.41B EV / Sales 2026 *
311x
EV / Sales 2027 * 2.39x
Free-Float
82.94%
Yield 2026 *
-
Yield 2027 * -
1 day-0.49%
1 week+0.66%
Current month-0.89%
1 month+5.90%
3 months+19.14%
6 months+5.72%
Current year+3.92%
1 week 6.03
Extreme 6.03
6.43
1 month 5.25
Extreme 5.25
6.46
Current year 3.88
Extreme 3.88
8.67
1 year 3.25
Extreme 3.25
13.5
3 years 2.28
Extreme 2.2801
17.6
5 years 2.28
Extreme 2.2801
356.4
10 years 2.28
Extreme 2.2801
356.4
Manager TitleAgeSince
Chief Executive Officer 59 01/04/2013
Chief Tech/Sci/R&D Officer 67 01/01/2013
Director of Finance/CFO 57 01/02/2022
Director TitleAgeSince
Director/Board Member 78 01/03/2013
Chairman 65 19/05/2021
Director/Board Member 49 01/12/2020
Date Insider Type Main position Quantity % Market Cap.
11/06Free

Chief Financial Officer

15,000 0.1174%
11/06Free

Chief Executive Officer

65,000 0.5087%
11/06Free

Founder

45,000 0.3522%
Change 5-day change 1-year change 3-year change Capi.($)
-0.49%+0.66%+56.41%-64.94% 77.95M
+0.68%+5.92%+80.45%+137.78% 59.1B
+2.32%+5.03%+75.51%+94.88% 55.19B
+3.86%+6.93%-11.32%-9.53% 24.67B
+4.30%+7.95%+14.11%+437.83% 24.19B
+4.74%+13.68%+45.58%-1.42% 19.69B
-0.29%+9.78%+44.62%-27.94% 17.56B
0.00%+20.78%+178.93%+360.74% 16.22B
+3.50%+1.97%+21.02%+191.95% 14.04B
+6.72%+19.38%+42.82% - 14.84B
Average +2.53%+8.25%+54.81%+124.37% 24.56B
Weighted average by Cap. +2.46%+6.47%+59.06%+137.64%

Financials

2026 *2027 *
Net sales 207K 181K 167K 155K 295K 19.75M 299K 2M 778K 9.71M 778K 762K 33.45M 23.64M 20.67M 19M 17.71M 33.58M 2.25B 34.09M 228M 88.65M 1.11B 88.75M 86.85M 3.81B
Net income -25.09M -21.94M -20.16M -18.79M -35.64M -2.39B -36.18M -242M -94.09M -1.17B -94.19M -92.17M -4.05B -27.55M -24.08M -22.13M -20.63M -39.13M -2.62B -39.72M -266M -103M -1.29B -103M -101M -4.44B
Net Debt -13.4M -11.71M -10.77M -10.03M -19.03M -1.28B -19.32M -129M -50.24M -627M -50.3M -49.22M -2.16B -21.4M -18.71M -17.19M -16.03M -30.4M -2.04B -30.86M -206M -80.24M -1B -80.33M -78.6M -3.45B
Logo Clene Inc.
Clene Inc. is a clinical-stage pharmaceutical company, which is engaged in discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The CSN therapeutics are comprised of atoms of transition elements that, when assembled in nanocrystal form, possess unusually high, unique catalytic activities that do not present in those same elements in bulk form. CNM-Au8, the lead drug asset, is a concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals for the treatment of ALS, MS, and PD. CNM-Au8's mechanism of action targets mitochondrial dysfunction by catalyzing the production of nicotinamide adenine dinucleotide. Its CNM-ZnAg is an antiviral and antibacterial agent comprised of zinc (Zn2+) and silver (Ag+) ions in an aqueous solution to treat infectious disease and to provide immune support for symptom resolution.
Employees
78
Date Price Change Volume
02/07/26 USD 6.100 -0.49% 30,035
01/07/26 USD 6.130 -0.41% 37,996
30/06/26 USD 6.155 -2.84% 75,802
29/06/26 USD 6.335 +4.54% 106,316
26/06/26 USD 6.060 +4.66% 104,311
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
6.100USD
Average target price
32.20USD
Spread / Average Target
+427.87%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CLNN Stock